Overview

Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

Status:
Completed

Trial end date:
2002-12-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.

Phase:

Phase 4

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Long-Acting
Isophane insulin, beef
Isophane Insulin, Human